Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds
This study has been completed.
Sponsor:
Healthpoint
Information provided by (Responsible Party):
Healthpoint
ClinicalTrials.gov Identifier:
NCT01190865
First received: August 26, 2010
Last updated: December 1, 2011
Last verified: December 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goal for this study is to examine the persistence of growth arrested,allogeneic,male-donor keratinocytes and fibroblasts when applied as product HP802-247 to the surface of acute excisional wounds in health female volunteers, as measured using Y-STR for detection of Y-chromosome.
| Condition | Intervention | Phase |
|---|---|---|
|
Normal Female Volunteers |
Biological: HP802-247 |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase I Study Investigating the Survival of HP802-247 Allogeneic Cells in Excisional Acute Cutaneous Wounds |
Further study details as provided by Healthpoint:
Primary Outcome Measures:
- Presence of Y Chromosome Genetic Markers [ Time Frame: 57 Days ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Identification of Donor Cell Type [ Time Frame: 57 Days ] [ Designated as safety issue: No ]
| Enrollment: | 28 |
| Study Start Date: | September 2010 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
HP802-247
Assessment Duration = 8 days Assessment Duration = 15 days Assessment Duration = 22 days Assessment Duration = 29 days Assessment Duration = 31 days Assessment Duration = 43 days Assessment Duration = 50 days Assessment Duration = 57 days
|
Biological: HP802-247
One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Provide written informed consent.
- Female, 18 years of age or older.
- Any race or skin type, provided that there are no tattoos within 5 cm of the wound target, and the gentian violet surgical marker produces a clearly visible mark on the skin.
- Willing to make all required study visits and, in the opinion of the Investigator, able to follow instructions.
- Willing to undergo the repeated biopsy procedures.
- Willing to undergo verification of sex chromosome status.
Exclusion Criteria:
- Males, or phenotypic females bearing Y-chromosome genetic material [e.g., 46,X,(r)Y; 46,X,der(X)t(X;Y); sex reassignment surgery].
- Contraindications or hypersensitivity to the use of the study medications or their components (e.g., history of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, or amphotericin B).
- History of keloid formation or hypertrophic scarring.
- Participation in any interventional clinical trial within 30 days prior to screening.
- History of prolonged bleeding, bleeding into joints, easy bruising following minor trauma, clotting factor deficiency, or current use of anticoagulants or platelet inhibitors.
- Any medical condition which, in the opinion of the Co-Investigator, may interfere with normal wound repair.
- Current therapy with drugs or biologics intended to function as immuno-suppressants, chronic (> 10 days) oral corticosteroids, or any concomitant medication which, in the opinion of the Co-Investigator, may interfere with normal wound repair.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01190865
Locations
| United States, Texas | |
| RCTS, Inc. | |
| Irving, Texas, United States | |
Sponsors and Collaborators
Healthpoint
Investigators
| Study Chair: | Herbert B Slade, MD | Healthpoint, Ltd |
| Principal Investigator: | Barry Reece, MS | RCTS, Inc. |
More Information
No publications provided
| Responsible Party: | Healthpoint |
| ClinicalTrials.gov Identifier: | NCT01190865 History of Changes |
| Other Study ID Numbers: | 802-247-09-021 |
| Study First Received: | August 26, 2010 |
| Last Updated: | December 1, 2011 |
| Health Authority: | United States: Food and Drug Administration |
ClinicalTrials.gov processed this record on May 21, 2013